Skip to main content

PROYECTO PRINCE; PREDICTORES INMUNOLOGICOS DE INFECCION BRONQUIAL EN ENFERMEDADES RESPIRATORIAS CRONICAS

PI18/00311

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reduced airway levels of fatty-acid binding protein 4 in COPD, relationship with airway infection and disease severity

  • Perea, Lidia|||0000-0002-1624-0012
  • Rodrigo-Troyano, Ana
  • Cantó, Elisabet|||0000-0002-1782-1855
  • Domínguez-Álvarez, Marisol
  • Giner, Jordi|||0000-0002-3044-2059
  • Sánchez Reus, Ferran|||0000-0002-6800-5487
  • Villar, Judit|||0000-0003-2813-8426
  • Quero, Sara|||0000-0002-6454-6358
  • Garcia-Nuñez, Marian|||0000-0002-5158-3758
  • Marín, Alicia|||0000-0002-9358-2120
  • Monso, Eduard|||0000-0003-1876-3092
  • Faner, Rosa|||0000-0002-8159-0115
  • Agustí, Àlvar
  • Vidal, Silvia|||0000-0002-3909-6682
  • Sibila, Oriol|||0000-0002-4833-6713
For still unclear reasons, chronic airway infection often occurs in patients with Chronic Obstructive Pulmonary Disease (COPD), particularly in those with more severe airflow limitation. Fatty-acid binding protein 4 (FABP4) is an adipokine involved in the innate immune response against infection produced by alveolar macrophages (Mɸ). We hypothesized that airway levels of FABP4 may be altered in COPD patients with chronic airway infection. In this prospective and controlled study we: (1) compared airway FABP4 levels (ELISA) in induced sputum, bronchoalveolar lavage fluid (BALF) and plasma samples in 52 clinically stable COPD patients (65.2 ± 7.9 years, FEV 59 ± 16% predicted) and 29 healthy volunteers (55.0 ± 12.3 years, FEV 97 ± 16% predicted); (2) explored their relationship with the presence of bacterial airway infection, defined by the presence of potentially pathogenic bacteria (PPB) at ≥10 3 colony-forming units/ml in BALF; (3) investigated their relationship with the quantity and proportion of Mɸ in BALF (flow cytometry); and, (4) studied their relationship with the severity of airflow limitation (FEV), GOLD grade and level of symptoms (CAT questionnaire). We found that: (1) airway levels of FABP4 (but not plasma ones) were reduced in COPD patients vs. controls [219.2 (96.0-319.6) vs. 273.4 (203.1-426.7) (pg/ml)/protein, p = 0.03 in BALF]; (2) COPD patients with airway infection had lower sputum FABP4 levels [0.73 (0.35-15.3) vs. 15.6 (2.0-29.4) ng/ml, p = 0.02]; (3) in COPD patients, the number and proportion of Mɸ were positively related with FABP4 levels in BALF; (4) BALF and sputum FABP4 levels were positively related with FEV, negatively with the CAT score, and lowest in GOLD grade D patients. Airway FABP4 levels are reduced in COPD patients, especially in those with airway infection and more severe disease. The relationship observed between Mɸ and airway FABP4 levels supports a role for FABP4 in the pathogenesis of airway infection and disease severity in COPD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Breath analysis using electronic nose and gas chromatography-mass spectrometry, A pilot study on bronchial infections in bronchiectasis

  • Fontes de Oliveira, Luciana
  • Mallafré-Muro, Celia
  • Giner, Jordi|||0000-0002-3044-2059
  • Perea, Lidia|||0000-0002-1624-0012
  • Sibila, Oriol|||0000-0002-4833-6713
  • Pardo, Antonio|||0000-0003-4369-544X
  • Marco, Santiago
Background and aims: In this work, breath samples from clinically stable bronchiectasis patients with and without bronchial infections by Pseudomonas Aeruginosa- PA) were collected and chemically analysed to determine if they have clinical value in the monitoring of these patients. Materials and methods: A cohort was recruited inviting bronchiectasis patients (25) and controls (9). Among the former group, 12 members were suffering PA infection. Breath samples were collected in Tedlar bags and analyzed by e-nose and Gas Chromatography-Mass Spectrometry (GC-MS). The obtained data were analyzed by chemometric methods to determine their discriminant power in regards to their health condition. Results were evaluated with blind samples. Results: Breath analysis by electronic nose successfully separated the three groups with an overall classification rate of 84% for the three-class classification problem. The best discrimination was obtained between control and bronchiectasis with PA infection samples 100% (CI: 84-100%) on external validation and the results were confirmed by permutation tests. The discrimination analysis by GC-MS provided good results but did not reach proper statistical significance after a permutation test. Conclusions: Breath sample analysis by electronic nose followed by proper predictive models successfully differentiated between control, Bronchiectasis and Bronchiectasis PA samples.